Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer
01 Jun 2023
Executive Change
Name change to Abilita Therapeutics reflects the company's focus and newly established capabilities to build an internal pipeline of first- and best-in-class therapeutics
Abilita Therapeutics strengthens leadership team by appointing Joel Edwards as chief business officer to advance corporate strategy and partnering efforts
SAN DIEGO, June 1, 2023 /PRNewswire/ -- Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics. The name change reflects the company's new focus on both discovery and early preclinical development. The company also expanded its mission to generate first- and best-in-class therapeutics for development and commercialization through partnerships. The company has four active antibody programs, highlighting the power of Abilita Therapeutics' EMP™ platform. Abilita Therapeutics' expanded focus uniquely positions the company to build value in historically challenging membrane protein targets, making previously undruggable targets druggable.
Aligned with the company's expanded mission, Abilita Therapeutics announced the appointment of Joel Edwards as chief business officer, effective June 1, 2023. He will serve as a member of Abilita Therapeutic's executive leadership team and report to Mauro Mileni, Ph.D., Abilita Therapeutic's chief executive officer. Mr. Edwards will lead Abilita Therapeutics' corporate strategy and business development efforts to maximize the value of the company's EMP™ discovery platform and pipeline through strategic partnerships.
"I'm excited to have Mr. Edwards join Abilita Therapeutics at this pivotal time in our company's evolution. We now have the tools and team in place to create high-quality development candidates for historically challenging membrane protein targets and drive value creation through partnerships," said Dr. Mileni. "Mr. Edwards brings extensive experience from both established biopharma and startup companies that will be instrumental as we pursue key partnerships for our current pipeline and strategic relationships, leveraging our EMP™ discovery platform to create additional first- and best-in-class therapeutics for patients with unmet needs."
Mr. Edwards has 23 years of industry experience and joins Abilita Therapeutics from Biosion USA, Inc., where he served as chief business officer, playing an integral role in closing their B round financing and two significant partnerships in 2022. Previously, he was vice president of corporate strategy and operations at Ionis Pharmaceuticals. During his 13-year tenure at Ionis, he executed strategic transactions and managed partnerships that generated greater than $3.5B in revenue, including management of Ionis' partnership with Biogen which resulted in the approval of SPINRAZA® for spinal muscular atrophy (SMA). Before that, Mr. Edwards held various business and scientific roles at Valeant Pharmaceuticals and Lexicon Pharmaceuticals. Mr. Edwards earned his M.B.A. from Colorado State University. He received his B.S. in Psychology from Ball State University.
About Abilita Therapeutics
Abilita Therapeutics, Inc. is a privately held, innovation-driven biotechnology company focused on discovering and developing therapeutics targeting the most challenging and medically important multi-span membrane proteins across a variety of indications. GPCRs, ion channels, and transporters are the targets of about 60% of today's medicines, highlighting their medical importance. However, only a small fraction of these proteins have been successfully drugged. Abilita Therapeutics' validated drug discovery engine builds on the foundation of its powerful EMP™ target evolution platform and deep membrane protein expertise to a suite of internal discovery technologies to create important therapeutics for previously undruggable targets. For more information, visit www.abilitatx.com.
Contact:
Mauro Mileni
[email protected]
858-246-6778
SOURCE Abilita Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.